title: Radiopharmaceuticals as orphan drugs.
abstract: Rare diseases and conditions are defined as diseases or conditions that affect less than 200,000 individuals in the United States. Because of the limited population suffering from any given rare disorder, there is little economic motivation for the development of drug products for its diagnosis or treatment. Also, frequently these rare diseases are misdiagnosed or undiagnosed due to a lack of familiarity with their symptoms and course. Thus, these rare disorders are commonly referred to as orphan diseases or conditions. To address this problem, legislation has been enacted that provides for incentives for the development of drug products for rare diseases or conditions (i.e., orphan drug products). Nuclear medicine scientists can take advantage of these incentives in the development of orphan radiopharmaceuticals for the treatment or diagnosis of rare diseases or conditions. Nuclear medicine physicians should know where information on orphan diseases and orphan radiopharmaceuticals can be obtained to maximize the care of their patients.
authors.affiliation: School of Pharmacy, University of Pittsburgh, PA, USA.
authors.forename: D P
authors.initials: DP
authors.lastname: Swanson
mesh_terms: D004194:Disease / Q000145:classification; D004813:Epidemiology; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy; D009965:Orphan Drug Production / Q000145:classification* / Q000191:economics / Q000331:legislation & jurisprudence; D011859:Radiography; D011868:Radioisotopes / Q000145:classification* / Q000191:economics; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
chemical_list: D011868:Radioisotopes